4.7 Article

Identification of phosphoenolpyruvate carboxykinase 1 as a potential therapeutic target for pancreatic cancer

期刊

CELL DEATH & DISEASE
卷 12, 期 10, 页码 -

出版社

SPRINGERNATURE
DOI: 10.1038/s41419-021-04201-w

关键词

-

资金

  1. National Natural Science Foundation [81773192, 82072712]
  2. Natural Science Foundation of Jiangsu Province [BK20171248]
  3. Jiangsu Youth Medical Talents Project [QNRC2016527]

向作者/读者索取更多资源

PCK1 is significantly elevated in human pancreatic cancer tissues and cells, and its silencing inhibits cell proliferation and induces apoptosis. Conversely, overexpression of PCK1 in pancreatic cancer cells accelerates cell proliferation and migration. In vivo, PCK1 silencing suppresses tumor growth and Akt-mTOR activation in xenograft tissues.
Pancreatic cancer is the third leading cause of cancer-related mortalities and is characterized by rapid disease progression. Identification of novel therapeutic targets for this devastating disease is important. Phosphoenolpyruvate carboxykinase 1 (PCK1) is the rate-limiting enzyme of gluconeogenesis. The current study tested the expression and potential functions of PCK1 in pancreatic cancer. We show that PCK1 mRNA and protein levels are significantly elevated in human pancreatic cancer tissues and cells. In established and primary pancreatic cancer cells, PCK1 silencing (by shRNA) or CRISPR/Cas9-induced PCK1 knockout potently inhibited cell growth, proliferation, migration and invasion, and induced robust apoptosis activation. Conversely, ectopic overexpression of PCK1 in pancreatic cancer cells accelerated cell proliferation and migration. RNA-seq analyzing of differentially expressed genes (DEGs) in PCK1-silenced pancreatic cancer cells implied that DEGs were enriched in the PI3K-Akt-mTOR cascade. In pancreatic cancer cells, Akt-mTOR activation was largely inhibited by PCK1 shRNA, but was augmented after ectopic PCK1 overexpression. In vivo, the growth of PCK1 shRNA-bearing PANC-1 xenografts was largely inhibited in nude mice. Akt-mTOR activation was suppressed in PCK1 shRNA-expressing PANC-1 xenograft tissues. Collectively, PCK1 is a potential therapeutic target for pancreatic cancer.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据